Profile review: 2026-11-05 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Clinical PK, mass spectrometry, immunoassays and biomarkers
Specialist contract research/testing services
Offers NCA and compartmental PK/PD analysis, supporting BA/BE, food-effect, DDI and dose-escalation studies.
Program / service
Target / indication
Representative stage
Evidence & scope
NCA / compartmental PK/PD
Plasma, whole-blood and urine data; suitability is study-specific · Not applicable; population depends on protocol
Services / platform
Clinical research service, not the company’s therapeutic product
Clinical PK reporting
Study-design input, analysis and PK/PD interpretation for ICH study reports · Not applicable; population depends on protocol
Services / platform
Clinical research service, not the company’s therapeutic product
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
European Journal of Drug Metabolism and Pharmacokinetics
A study in European Journal of Drug Metabolism and Pharmacokinetics modeled subcutaneous aqueous progesterone using single-dose crossover data from 50 healthy Chinese postmenopausal women. Machine-learning approaches screened potential covariates before conventional PopPK evaluation. Height and body-weight effects remained statistically identifiable but had limited clinical significance. Simulated repeated-dose exposure is model-derived, rather than an observed efficacy outcome in fertility patients.
On November 5, PharmaIN reported conference findings from PHIN-001: 12 participants with Child-Pugh B cirrhosis received PHIN-214; 10 completed 28 days. The issuer described Grade 1–2 treatment-related adverse events and exploratory renal, hemodynamic and PK findings. The ongoing small Phase 1 study does not establish clinical benefit. This is a company conference announcement, not a peer-reviewed paper.
Ethris reported topline results from a randomized Phase 2a rhinovirus-challenge study involving 50 adults with asthma. A single nasal dose of ETH47, an interferon-lambda-encoding mRNA candidate, produced local expression and lower day-two viral load. Symptom improvements were described as numerical trends; exposure-response subgroup findings remain exploratory, without established clinical efficacy.
